NovaBridge Biosciences licenses VIS-102
- License agreement with Hiteck for VIS-102 worldwide excluding Greater China
- $7.0 million upfront and near-term milestone payment
- Potential additional payments of up to $104.0 million
IMAB
NovaBridge Biosciences SEC filings
Every EDGAR filing for NovaBridge Biosciences (IMAB), newest first, with AI summaries and stories.
- Ticker
- IMAB
- CIK
- 1778016
- Latest filing
- 6d
Insider activity
No open-market insider buys in the last 30 days.
Also: 1 open-market sale ($6K), 1 grant or exercise.
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE6-KNovaBridge BiosciencesNBPLIVE ROUTINE4NovaBridge BiosciencesIMABLIVE Phillip Andrew Dennis, insider filing for IMAB
Phillip Andrew Dennis, reporting
ROUTINE144NovaBridge BiosciencesNBPLIVE Phillip Andrew Dennis, planned sale of NBP shares
Phillip Andrew Dennis, reporting
ROUTINE4NovaBridge BiosciencesIMABLIVE Sean Wuxiong Cao, insider filing for IMAB
Sean Wuxiong Cao, reporting
ROUTINE3NovaBridge BiosciencesNBPLIVE Martin William Dewhurst, new insider at NBP
Martin William Dewhurst, reporting
ROUTINE144NovaBridge BiosciencesIMABLIVE Sean Wuxiong Cao, planned sale of IMAB shares
Sean Wuxiong Cao, reporting
ROUTINE4NovaBridge BiosciencesNBPLIVE Sean Wuxiong Cao, insider filing for NBP
Sean Wuxiong Cao, reporting
ROUTINE6-KNovaBridge BiosciencesNBPLIVE ROUTINE6-KNovaBridge BiosciencesNBPLIVE ROUTINE4NovaBridge BiosciencesIMABLIVE Cong Claire Xu, insider filing for IMAB
Cong Claire Xu, reporting
ROUTINE4NovaBridge BiosciencesNBPLIVE Robert A. Lenz, insider filing for NBP
Robert A. Lenz, reporting
ROUTINE6-KNovaBridge BiosciencesIMABLIVE ROUTINE6-KNovaBridge BiosciencesIMABLIVE ROUTINES-8NovaBridge BiosciencesNBPLIVE ROUTINE6-KNovaBridge BiosciencesNBPLIVE ROUTINE6-KNovaBridge BiosciencesIMABLIVE ROUTINE4NovaBridge BiosciencesNBPLIVE 2 insider filings
Liwei Lorraine Lin, insider filing for NBP
Show all 2
- 4Insider filing for NBP
- 4Insider filing for NBP
Liwei Lorraine Lin, reporting
ROUTINE4NovaBridge BiosciencesNBPLIVE 2 insider filings
Srishti Gupta, insider filing for NBP
Show all 2
- 4Insider filing for NBP
- 3New insider at NBP
Srishti Gupta, reporting
ROUTINE4NovaBridge BiosciencesIMABLIVE Cong Claire Xu, insider filing for IMAB
Cong Claire Xu, reporting
ROUTINE4NovaBridge BiosciencesNBPLIVE Wei Fu, insider filing for NBP
Wei Fu, reporting
ROUTINE6-KNovaBridge BiosciencesIMABLIVE ROUTINE4NovaBridge BiosciencesNBPLIVE Sean Wuxiong Cao, insider filing for NBP
Sean Wuxiong Cao, reporting
ROUTINE4NovaBridge BiosciencesNBPLIVE Phillip Andrew Dennis, insider filing for NBP
Phillip Andrew Dennis, reporting
ROUTINE20-F/ANovaBridge BiosciencesNBPLIVE ROUTINE6-KNovaBridge BiosciencesNBPLIVE ROUTINE6-KNovaBridge BiosciencesNBPLIVE ROUTINE4NovaBridge BiosciencesNBPLIVE Cong Claire Xu, insider filing for NBP
Cong Claire Xu, reporting
ROUTINE4NovaBridge BiosciencesIMABLIVE Sean Wuxiong Cao, insider filing for IMAB
Sean Wuxiong Cao, reporting
ROUTINE144NovaBridge BiosciencesIMABLIVE Sean Wuxiong Cao, planned sale of IMAB shares
Sean Wuxiong Cao, reporting
ROUTINE4NovaBridge BiosciencesIMABLIVE Mark Arnold Hagler, insider filing for IMAB
Mark Arnold Hagler, reporting
ROUTINE3NovaBridge BiosciencesIMABLIVE Mark Arnold Hagler, new insider at IMAB
Mark Arnold Hagler, reporting
ROUTINE6-KNovaBridge BiosciencesIMABLIVE ROUTINE3/ANovaBridge BiosciencesIMABLIVE Cong Claire Xu, new insider at IMAB (amended)
Cong Claire Xu, reporting
ROUTINE6-KNovaBridge BiosciencesNBPLIVE NOTABLE20-FNovaBridge BiosciencesNBPLIVE ROUTINE3NovaBridge BiosciencesNBPLIVE Conor Chia-hung Yang, new insider at NBP
Conor Chia-hung Yang, reporting
ROUTINE3NovaBridge BiosciencesNBPLIVE Denny Hsueh Wen Chu, new insider at NBP
Denny Hsueh Wen Chu, reporting
ROUTINE3NovaBridge BiosciencesIMABLIVE Phillip Andrew Dennis, new insider at IMAB
Phillip Andrew Dennis, reporting
ROUTINE3NovaBridge BiosciencesIMABLIVE 10 insider filings
Liwei Lorraine Lin, new insider at IMAB
Show all 10
- 3New insider at IMAB
- 3New insider at IMAB
- 3New insider at NBP
- 3New insider at IMAB
- 3New insider at NBP
- 3New insider at NBP
- 3New insider at NBP
- 3New insider at NBP
- 3New insider at IMAB
- 3New insider at NBP
Liwei Lorraine Lin, reporting